|
|
Line 822: |
Line 822: |
| *Normal. | | *Normal. |
|
| |
|
| =Transplant= | | =Renal transplant pathology= |
| ===General===
| | {{Main|Renal transplant pathology}} |
| Rejection can be:
| |
| *Acute.
| |
| *Chronic.
| |
| *Acute-on-chronic.
| |
|
| |
|
| ====Acute====
| | *Acute rejection. |
| *Acute rejection has a standardized classification ''Banff classification''.<ref name=pmid9987096>{{cite journal |author=Racusen LC, Solez K, Colvin RB, ''et al.'' |title=The Banff 97 working classification of renal allograft pathology |journal=Kidney Int. |volume=55 |issue=2 |pages=713–23 |year=1999 |month=February |pmid=9987096 |doi=10.1046/j.1523-1755.1999.00299.x |url=http://www.nature.com/ki/journal/v55/n2/full/4490631a.html}}</ref> | | *Chronic rejection. |
| | | *[[Polyomavirus]]. |
| Diagnosis of acute rejection requires:
| | *[[Transplant glomerulopathy]]. |
| #Serology.
| | *Calcineurin-inhibitor toxicity. |
| #IHC (C4d).
| |
| #*This is somewhat debated.
| |
| #Morphology.
| |
| | |
| ===Predictors===
| |
| *Associated with C4d+ IHC.<ref name=pmid1747954>Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Feucht HE, Felber E, Gokel MJ, Hillebrand G, Nattermann U, Brockmeyer C, Held E, Riethmüller G, Land W, Albert E. Clin Exp Immunol. 1991 Dec;86(3):464-70. PMID 1747954.</ref> | |
| *Mean graft survival is ~4 years for C4d+ interstitial capillaries vs. ~8 years for C4d- renal grafts.<ref name=pmid11135088>Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Lederer SR, Kluth-Pepper B, Schneeberger H, Albert E, Land W, Feucht HE. Kidney Int. 2001 Jan;59(1):334-41. PMID 11135088.</ref>
| |
| | |
| ===Polyomavirus===
| |
| *This bad-boy is associated with failure of transplanted kidneys.<ref name=pmid216990>{{cite journal |author=Mackenzie EF, Poulding JM, Harrison PR, Amer B |title=Human polyoma virus (HPV)--a significant pathogen in renal transplantation |journal=Proc Eur Dial Transplant Assoc |volume=15 |issue= |pages=352–60 |year=1978 |pmid=216990 |doi= |url=}}</ref>
| |
| *Treatment: reduce immunosuppression.<ref name=Nickeleit>Nickeleit, Volker; Singh, Harsharan K. Polyomavirus Allograft Nephropathy: Clinico-Pathological Correlations. URL: [http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=eurekah&part=A74503#A74539 http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=eurekah&part=A74503#A74539]. Accessed on: 8 November 2010.</ref> | |
| | |
| Microscopic features:<ref name=Nickeleit/>
| |
| *Ground glass-like nuclear inclusions.
| |
| *Nuclear enlargement.
| |
| | |
| ===Transplant glomerulopathy===
| |
| Microscopic:
| |
| *Tram-tracking of basement membrane.
| |
| | |
| DDx (tram-tracking):
| |
| *[[MPGN]].
| |
| *[[Thrombotic microangiopathy]] (TMA). | |
| | |
| ===Calcineurin-inhibitor toxicity===
| |
| *Calcineurin-inhibitors (e.g. cyclosporine,<ref name=pmid10354295>{{cite journal |author=Zarifian A, Meleg-Smith S, O'donovan R, Tesi RJ, Batuman V |title=Cyclosporine-associated thrombotic microangiopathy in renal allografts |journal=Kidney Int. |volume=55 |issue=6 |pages=2457–66 |year=1999 |month=June |pmid=10354295 |doi=10.1046/j.1523-1755.1999.00492.x |url=}}</ref>, tacrolimus<ref name=Ref_FoRP203>{{Ref FoRP|203}}</ref>) toxicity can induce a [[thrombotic microangiopathy]].
| |
| *Hyaline arteriopathy with a peripheral and nodular distribution (chronic toxicity).
| |
|
| |
|
| =See also= | | =See also= |